Tekla Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Tekla Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-70,000	Closed	-$465K	–	198
2018 Q4	$465K	Hold	70,000	–	–	0.02%	189
2018 Q3	$747K	Buy	+70,000	New	+$802K	0.03%	187
2018 Q2	–	Sell	-231,054	Closed	-$1.98M	–	184
2018 Q1	$1.98M	Sell	231,054 -47,646	-17%	-$441K	0.08%	136
2017 Q4	$2.75M	Buy	+278,700	New	+$2.9M	0.11%	113
2016 Q2	–	Sell	-197,641	Closed	-$2.36M	–	161
2016 Q1	$2.36M	Hold	197,641	–	–	0.1%	111
2015 Q4	$2.63M	Sell	197,641 -156,259	-44%	-$1.92M	0.1%	112
2015 Q3	$3.8M	Buy	+353,900	New	+$3.87M	0.14%	112

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's LXRX Position: Q1 2019 in Review

Tekla Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 70,000 shares — an estimated $465K sold.

Tekla Capital Management first reported a position in LXRX in Q3 2015 and held it in 7 quarters. The position peaked at $3.8M in Q3 2015. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

Tekla Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Tekla Capital Management sold 70,000 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $465K.
Tekla Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 7 quarters.
Tekla Capital Management's Lexicon Pharmaceuticals position peaked at $3.8M in Q3 2015.
121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.